Immunovant, Inc.
For the period ended Mar 31, 2026. Filed May 20, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed May 20, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 9B. OTHER INFORMATION
During the three months ended March 31, 2026, none of our directors or Section 16 reporting officers adopted, modified orterminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of the SEC’s Regulation S-K) with respect to the trading of Immunovant common stock.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.